显示样式:     当前期刊: Nature Reviews Endocrinology    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Emerging nonmetabolic functions of skin fat
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2018-01-12
    Christian F. Guerrero-Juarez, Maksim V. Plikus

    Although the major white adipose depots evolved primarily to store energy, secrete hormones and thermo-insulate the body, multiple secondary depots developed additional specialized and unconventional functions. Unlike any other fat tissue, dermal white adipose tissue (dWAT) evolved a large repertoire of novel features that are central to skin physiology, which we discuss in this Review. dWAT exists in close proximity to hair follicles, the principal appendages of the skin that periodically grow new hairs. Responding to multiple hair-derived signals, dWAT becomes closely connected to cycling hair follicles and periodically cycles itself. At the onset of new hair growth, hair follicles secrete activators of adipogenesis, while at the end of hair growth, a reduction in the secretion of activators or potentially, an increase in the secretion of inhibitors of adipogenesis, results in fat lipolysis. Hair-driven cycles of dWAT remodelling are uncoupled from size changes in other adipose depots that are controlled instead by systemic metabolic demands. Rich in growth factors, dWAT reciprocally signals to hair follicles, altering the activation state of their stem cells and modulating the pace of hair regrowth. dWAT cells also facilitate skin repair following injury and infection. In response to wounding, adipose progenitors secrete repair-inducing activators, while bacteria-sensing adipocytes produce antimicrobial peptides, thus aiding innate immune responses in the skin.

    更新日期:2018-01-12
  • Diabetes: Towards a coxsackievirus B-based vaccine to combat T1DM
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2018-01-12
    Didier Hober, Enagnon Kazali Alidjinou

    Diabetes: Towards a coxsackievirus B-based vaccine to combat T1DM Diabetes: Towards a coxsackievirus B-based vaccine to combat T1DM, Published online: 12 January 2018; doi:10.1038/nrendo.2017.184 The role of group B coxsackieviruses (CVB) in the pathogenesis of type 1 diabetes mellitus (T1DM) remains controversial. A recent report by Stone et al. showed that a CVB1-based vaccine can protect against both CVB1 infection and CVB1-induced T1DM in mouse models. This tool could help to elucidate the relationship between CVB and T1DM.

    更新日期:2018-01-12
  • Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2018-01-05
    Rury R. Holman

    Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trialsManagement of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials, Published online: 05 January 2018; doi:10.1038/nrendo.2017.179The risk of death from cardiovascular causes in people with type 2 diabetes mellitus remains around twice that in the general population, with heart failure a common event. In 2017, results from cardiovascular outcome trials in people with diabetes mellitus showed that some drugs have dual utility — reducing cardiovascular risk and improving glycaemic control.

    更新日期:2018-01-05
  • Adipose tissue: The dysfunctional adipocyte — a cancer cell's best friend
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2018-01-05
    Zhuzhen Zhang, Philipp E. Scherer

    Adipose tissue: The dysfunctional adipocyte — a cancer cell's best friendAdipose tissue: The dysfunctional adipocyte — a cancer cell's best friend, Published online: 05 January 2018; doi:10.1038/nrendo.2017.174The interactions of adipocytes with tumour cells have been extensively scrutinized. The adipocyte's mitogenic influence on tumour cells is attributed to several hormonal, growth factor and adipokine effects. A recent study has expanded our understanding of how adipocytes promote tumour progression by demonstrating that adipocytes actively catabolize the chemotherapeutic agent daunorubicin.

    更新日期:2018-01-05
  • Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-29
    Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne

    Nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus are common diseases that often coexist and might act synergistically to increase the risk of hepatic and extra-hepatic clinical outcomes. NAFLD affects up to 70–80% of patients with type 2 diabetes mellitus and up to 30–40% of adults with type 1 diabetes mellitus. The coexistence of NAFLD and diabetes mellitus increases the risk of developing not only the more severe forms of NAFLD but also chronic vascular complications of diabetes mellitus. Indeed, substantial evidence links NAFLD with an increased risk of developing cardiovascular disease and other cardiac and arrhythmic complications in patients with type 1 diabetes mellitus or type 2 diabetes mellitus. NAFLD is also associated with an increased risk of developing microvascular diabetic complications, especially chronic kidney disease. This Review focuses on the strong association between NAFLD and the risk of chronic vascular complications in patients with type 1 diabetes mellitus or type 2 diabetes mellitus, thereby promoting an increased awareness of the extra-hepatic implications of this increasingly prevalent and burdensome liver disease. We also discuss the putative underlying mechanisms by which NAFLD contributes to vascular diseases, as well as the emerging role of changes in the gut microbiota (dysbiosis) in the pathogenesis of NAFLD and associated vascular diseases.

    更新日期:2017-12-31
  • Immunometabolism in 2017: Metabolism and the inflammasome in health and ageing
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-29
    Thomas Mandrup-Poulsen

    Immunometabolism in 2017: Metabolism and the inflammasome in health and ageing Immunometabolism in 2017: Metabolism and the inflammasome in health and ageing, Published online: 29 December 2017; doi:10.1038/nrendo.2017.175 Extracellular danger-associated molecular patterns signal to NOD-like receptors, but the exact signalling pathways remain unclear. The inflammasomes, a subgroup of these receptors, translate danger signals into inflammatory responses by maturing IL-1 and IL-18. In 2017, researchers reported novel functions of the mutual interaction between metabolism and the inflammasomes in health and disease.

    更新日期:2017-12-31
  • Neuropsychiatric disorders: Side effects of olanzapine worsened by metabolic dysfunction
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-29
    Ivone Leong

    Neuropsychiatric disorders: Side effects of olanzapine worsened by metabolic dysfunction Neuropsychiatric disorders: Side effects of olanzapine worsened by metabolic dysfunction, Published online: 29 December 2017; doi:10.1038/nrendo.2017.183 Neuropsychiatric disorders: Side effects of olanzapine worsened by metabolic dysfunction

    更新日期:2017-12-31
  • Growth and growth disorders in 2017: Genetic and epigenetic regulation of childhood growth
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-29
    Ola Nilsson

    Growth and growth disorders in 2017: Genetic and epigenetic regulation of childhood growth Growth and growth disorders in 2017: Genetic and epigenetic regulation of childhood growth, Published online: 29 December 2017; doi:10.1038/nrendo.2017.178 Studies of rare growth disorders taken together with large-scale genetic studies of adult height variability have uncovered a large genetic network regulating childhood growth. Advances in technology and experimental model systems will help decipher the molecular mechanisms of this complex network and lead to novel treatment approaches for growth disorders.

    更新日期:2017-12-31
  • Gut microbiota: Fibre restores healthy gut microbiota
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-29
    Alan Morris

    Gut microbiota: Fibre restores healthy gut microbiota Gut microbiota: Fibre restores healthy gut microbiota, Published online: 29 December 2017; doi:10.1038/nrendo.2017.182 Gut microbiota: Fibre restores healthy gut microbiota

    更新日期:2017-12-31
  • Nutraceuticals in 2017: Nutraceuticals in endocrine disorders
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-22
    Amanda J. Berberich, Robert A. Hegele

    Nutraceuticals in 2017: Nutraceuticals in endocrine disorders Nutraceuticals in 2017: Nutraceuticals in endocrine disorders, Published online: 22 December 2017; doi:10.1038/nrendo.2017.169 Nutraceuticals are gaining legitimacy and their potential clinical role is expanding. Data from 2017 provides evidence for their possible use in type 2 diabetes mellitus, the metabolic syndrome, obesity, dyslipidaemia and osteoporosis. Ongoing high-quality research in this area might justify future selective implementation of nutraceuticals into general health practice.

    更新日期:2017-12-22
  • Technology watch: AI can diagnose diabetic retinopathy
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-22
    Alan Morris

    Technology watch: AI can diagnose diabetic retinopathy Technology watch: AI can diagnose diabetic retinopathy, Published online: 22 December 2017; doi:10.1038/nrendo.2017.177 Technology watch: AI can diagnose diabetic retinopathy

    更新日期:2017-12-22
  • The artificial pancreas in 2017: The year of transition from research to clinical practice
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-22
    Boris Kovatchev

    The artificial pancreas in 2017: The year of transition from research to clinical practice The artificial pancreas in 2017: The year of transition from research to clinical practice, Published online: 22 December 2017; doi:10.1038/nrendo.2017.170 The artificial pancreas — the automated closed-loop control of diabetes mellitus — made its first outpatient strides in 2011. In 2017, the results of long-term clinical trials on the artificial pancreas were published, the first hybrid commercial artificial pancreas system was approved and the artificial pancreas was tested under increasingly demanding conditions. Thus, artificial pancreas technology is here to stay.

    更新日期:2017-12-22
  • Thyroid function: Thyroid hormone therapy resolves pulmonary fibrosis in mice
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-22
    Alan Morris

    Thyroid function: Thyroid hormone therapy resolves pulmonary fibrosis in mice Thyroid function: Thyroid hormone therapy resolves pulmonary fibrosis in mice, Published online: 22 December 2017; doi:10.1038/nrendo.2017.172 Thyroid function: Thyroid hormone therapy resolves pulmonary fibrosis in mice

    更新日期:2017-12-22
  • Therapy: Achieving T2DM remission in primary care
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-22
    Claire Greenhill

    Therapy: Achieving T2DM remission in primary care Therapy: Achieving T2DM remission in primary care, Published online: 22 December 2017; doi:10.1038/nrendo.2017.176 Therapy: Achieving T2DM remission in primary care

    更新日期:2017-12-22
  • Reproductive endocrinology: Restoring ovarian function
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-15
    Ivone Leong

    Reproductive endocrinology: Restoring ovarian function Reproductive endocrinology: Restoring ovarian function, Published online: 15 December 2017; doi:10.1038/nrendo.2017.171 Reproductive endocrinology: Restoring ovarian function

    更新日期:2017-12-15
  • Diabetes: ANGPTL8 as an early predictor of gestational diabetes mellitus
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-08
    Ivone Leong

    Diabetes: ANGPTL8 as an early predictor of gestational diabetes mellitus Diabetes: ANGPTL8 as an early predictor of gestational diabetes mellitus, Published online: 08 December 2017; doi:10.1038/nrendo.2017.167 Diabetes: ANGPTL8 as an early predictor of gestational diabetes mellitus

    更新日期:2017-12-10
  • Obesity: Sex differences in insulin resistance
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-08
    Claire Greenhill

    Obesity: Sex differences in insulin resistance Obesity: Sex differences in insulin resistance, Published online: 08 December 2017; doi:10.1038/nrendo.2017.168 Obesity: Sex differences in insulin resistance

    更新日期:2017-12-10
  • Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-08
    Yan Zheng, Sylvia H. Ley, Frank B. Hu

    Global aetiology and epidemiology of type 2 diabetes mellitus and its complications Global aetiology and epidemiology of type 2 diabetes mellitus and its complications, Published online: 08 December 2017; doi:10.1038/nrendo.2017.151 The global epidemic of type 2 diabetes mellitus (T2DM) and its complications is a major threat to public health. This Review provides an updated view of the global epidemiology of T2DM and the dietary, lifestyle and other risk factors for T2DM and its complications.

    更新日期:2017-12-10
  • Immunotherapy: PDL1 restoration reverses T1DM
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-01
    Conor A. Bradley

    Immunotherapy: PDL1 restoration reverses T1DM Immunotherapy: PDL1 restoration reverses T1DM, Published online: 01 December 2017; doi:10.1038/nrendo.2017.165 Immunotherapy: PDL1 restoration reverses T1DM

    更新日期:2017-12-01
  • In the news
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-01
    Claire Greenhill

    In the news In the news, Published online: 01 December 2017; doi:10.1038/nrendo.2017.164 In the news

    更新日期:2017-12-01
  • Obesity: Ankyrin-B in susceptibility to obesity
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-12-01
    Ivone Leong

    Obesity: Ankyrin-B in susceptibility to obesity Obesity: Ankyrin-B in susceptibility to obesity, Published online: 01 December 2017; doi:10.1038/nrendo.2017.163 Obesity: Ankyrin-B in susceptibility to obesity

    更新日期:2017-12-01
  • Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    André J. Scheen

    Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors? Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors?, Published online: 24 November 2017; doi:10.1038/nrendo.2017.154 Three cardiovascular outcome trials failed to show superiority of DPP4 inhibitors compared with placebo in patients with type 2 diabetes mellitus and high cardiovascular risk, a rather disappointing finding. Now, a post hoc subgroup analysis suggests that patients treated with metformin at baseline might benefit from DPP4 inhibitors in contrast with metformin non-users.

    更新日期:2017-11-24
  • Thyroid cancer: CAR T cell therapy — potential in advanced thyroid cancer?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Jena D. French, Bryan R. Haugen

    Thyroid cancer: CAR T cell therapy — potential in advanced thyroid cancer? Thyroid cancer: CAR T cell therapy — potential in advanced thyroid cancer?, Published online: 24 November 2017; doi:10.1038/nrendo.2017.160 In the current era of immunotherapy successes, Min and colleagues report the promising preclinical development and efficacy of a CAR T cell therapy that recognizes ICAM-1, which is highly expressed in advanced thyroid cancers. Herein, we discuss the feasibility of this approach and its implications for future therapies to treat thyroid cancer.

    更新日期:2017-11-24
  • Adipose tissue: Noncanonical beige fat thermogenesis
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Conor A. Bradley

    Adipose tissue: Noncanonical beige fat thermogenesis Adipose tissue: Noncanonical beige fat thermogenesis, Published online: 24 November 2017; doi:10.1038/nrendo.2017.158 Adipose tissue: Noncanonical beige fat thermogenesis

    更新日期:2017-11-24
  • Long-term effects of adolescent obesity: time to act
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Thomas Reinehr

    Long-term effects of adolescent obesity: time to act Long-term effects of adolescent obesity: time to act, Published online: 24 November 2017; doi:10.1038/nrendo.2017.147 The incidence of adolescent obesity is increasing, which has serious long-term implications for the affected individuals and wider society. Here, Thomas Reinehr outlines the effects of adolescent obesity and discusses how the epidemic could be addressed.

    更新日期:2017-11-24
  • Obesity: Trends in underweight and obesity — scale of the problem
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Jack A. Yanovski

    Obesity: Trends in underweight and obesity — scale of the problem Obesity: Trends in underweight and obesity — scale of the problem, Published online: 24 November 2017; doi:10.1038/nrendo.2017.157 A recent study reports that the global prevalence of paediatric obesity increased to >5% between 1975 and 2016. This increase occurred even as the prevalence of paediatric underweight decreased slightly but remained >8%. These average prevalence changes blur the remarkable regional variations in how prevalence has changed. There is a pressing need to address both underweight and obesity worldwide.

    更新日期:2017-11-24
  • Diabetes: Very-low-calorie diet reverses T2DM in rats
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Alan Morris

    Diabetes: Very-low-calorie diet reverses T2DM in rats Diabetes: Very-low-calorie diet reverses T2DM in rats, Published online: 24 November 2017; doi:10.1038/nrendo.2017.159 Diabetes: Very-low-calorie diet reverses T2DM in rats

    更新日期:2017-11-24
  • Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    André J. Scheen

    Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors? Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors?, Published online: 24 November 2017; doi:10.1038/nrendo.2017.154 Three cardiovascular outcome trials failed to show superiority of DPP4 inhibitors compared with placebo in patients with type 2 diabetes mellitus and high cardiovascular risk, a rather disappointing finding. Now, a post hoc subgroup analysis suggests that patients treated with metformin at baseline might benefit from DPP4 inhibitors in contrast with metformin non-users.

    更新日期:2017-11-24
  • Thyroid cancer: CAR T cell therapy — potential in advanced thyroid cancer?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Jena D. French, Bryan R. Haugen

    Thyroid cancer: CAR T cell therapy — potential in advanced thyroid cancer? Thyroid cancer: CAR T cell therapy — potential in advanced thyroid cancer?, Published online: 24 November 2017; doi:10.1038/nrendo.2017.160 In the current era of immunotherapy successes, Min and colleagues report the promising preclinical development and efficacy of a CAR T cell therapy that recognizes ICAM-1, which is highly expressed in advanced thyroid cancers. Herein, we discuss the feasibility of this approach and its implications for future therapies to treat thyroid cancer.

    更新日期:2017-11-24
  • Adipose tissue: Noncanonical beige fat thermogenesis
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Conor A. Bradley

    Adipose tissue: Noncanonical beige fat thermogenesis Adipose tissue: Noncanonical beige fat thermogenesis, Published online: 24 November 2017; doi:10.1038/nrendo.2017.158 Adipose tissue: Noncanonical beige fat thermogenesis

    更新日期:2017-11-24
  • Long-term effects of adolescent obesity: time to act
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Thomas Reinehr

    Long-term effects of adolescent obesity: time to act Long-term effects of adolescent obesity: time to act, Published online: 24 November 2017; doi:10.1038/nrendo.2017.147 The incidence of adolescent obesity is increasing, which has serious long-term implications for the affected individuals and wider society. Here, Thomas Reinehr outlines the effects of adolescent obesity and discusses how the epidemic could be addressed.

    更新日期:2017-11-24
  • Obesity: Trends in underweight and obesity — scale of the problem
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Jack A. Yanovski

    Obesity: Trends in underweight and obesity — scale of the problem Obesity: Trends in underweight and obesity — scale of the problem, Published online: 24 November 2017; doi:10.1038/nrendo.2017.157 A recent study reports that the global prevalence of paediatric obesity increased to >5% between 1975 and 2016. This increase occurred even as the prevalence of paediatric underweight decreased slightly but remained >8%. These average prevalence changes blur the remarkable regional variations in how prevalence has changed. There is a pressing need to address both underweight and obesity worldwide.

    更新日期:2017-11-24
  • Diabetes: Very-low-calorie diet reverses T2DM in rats
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-24
    Alan Morris

    Diabetes: Very-low-calorie diet reverses T2DM in rats Diabetes: Very-low-calorie diet reverses T2DM in rats, Published online: 24 November 2017; doi:10.1038/nrendo.2017.159 Diabetes: Very-low-calorie diet reverses T2DM in rats

    更新日期:2017-11-24
  • Reproductive endocrinology: Exposure to pesticide residues linked to adverse pregnancy outcomes
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-17
    Alan Morris

    Reproductive endocrinology: Exposure to pesticide residues linked to adverse pregnancy outcomes Reproductive endocrinology: Exposure to pesticide residues linked to adverse pregnancy outcomes, Published online: 17 November 2017; doi:10.1038/nrendo.2017.156

    更新日期:2017-11-17
  • Cardiovascular endocrinology: Long-term safety of growth hormone
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-17
    Conor A. Bradley

    Cardiovascular endocrinology: Long-term safety of growth hormone Cardiovascular endocrinology: Long-term safety of growth hormone, Published online: 17 November 2017; doi:10.1038/nrendo.2017.155

    更新日期:2017-11-17
  • Reproductive endocrinology: Exposure to pesticide residues linked to adverse pregnancy outcomes
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-17
    Alan Morris

    Reproductive endocrinology: Exposure to pesticide residues linked to adverse pregnancy outcomes Reproductive endocrinology: Exposure to pesticide residues linked to adverse pregnancy outcomes, Published online: 17 November 2017; doi:10.1038/nrendo.2017.156

    更新日期:2017-11-17
  • Cardiovascular endocrinology: Long-term safety of growth hormone
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-17
    Conor A. Bradley

    Cardiovascular endocrinology: Long-term safety of growth hormone Cardiovascular endocrinology: Long-term safety of growth hormone, Published online: 17 November 2017; doi:10.1038/nrendo.2017.155

    更新日期:2017-11-17
  • Bone: High-intensity exercise to prevent fractures — risk or gain?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-10
    Wolfgang Kemmler, Simon von Stengel

    Bone: High-intensity exercise to prevent fractures — risk or gain? Bone: High-intensity exercise to prevent fractures — risk or gain?, Published online: 10 November 2017; doi:10.1038/nrendo.2017.148 NatureArticleSnippet(type=standfirst, markup= Although the favourable effects of high-intensity resistance and impact training (HiRIT) on bone strength have been demonstrated, it is generally considered unsuitable for older adults. A recent study reports that 8 months of HiRIT was efficacious and induced no adverse effects in older postmenopausal women with, or at risk of, osteoporosis. , isJats=true)

    更新日期:2017-11-11
  • Bone: PPARγ controls marrow adiposity
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-10
    Conor A. Bradley

    Bone: PPARγ controls marrow adiposity Bone: PPARγ controls marrow adiposity, Published online: 10 November 2017; doi:10.1038/nrendo.2017.152

    更新日期:2017-11-11
  • Metabolism: Metabolic effects of intermeal fasting
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-10
    Claire Greenhill

    Metabolism: Metabolic effects of intermeal fasting Metabolism: Metabolic effects of intermeal fasting, Published online: 10 November 2017; doi:10.1038/nrendo.2017.153

    更新日期:2017-11-11
  • Bone: High-intensity exercise to prevent fractures — risk or gain?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-10
    Wolfgang Kemmler, Simon von Stengel

    Bone: High-intensity exercise to prevent fractures — risk or gain? Bone: High-intensity exercise to prevent fractures — risk or gain?, Published online: 10 November 2017; doi:10.1038/nrendo.2017.148 NatureArticleSnippet(type=standfirst, markup= Although the favourable effects of high-intensity resistance and impact training (HiRIT) on bone strength have been demonstrated, it is generally considered unsuitable for older adults. A recent study reports that 8 months of HiRIT was efficacious and induced no adverse effects in older postmenopausal women with, or at risk of, osteoporosis. , isJats=true)

    更新日期:2017-11-11
  • Bone: PPARγ controls marrow adiposity
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-10
    Conor A. Bradley

    Bone: PPARγ controls marrow adiposity Bone: PPARγ controls marrow adiposity, Published online: 10 November 2017; doi:10.1038/nrendo.2017.152

    更新日期:2017-11-11
  • Metabolism: Metabolic effects of intermeal fasting
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-10
    Claire Greenhill

    Metabolism: Metabolic effects of intermeal fasting Metabolism: Metabolic effects of intermeal fasting, Published online: 10 November 2017; doi:10.1038/nrendo.2017.153

    更新日期:2017-11-11
  • Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Rutger Verbeek, G. Kees Hovingh

    Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes? Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes?, Published online: 09 November 2017; doi:10.1038/nrendo.2017.145 NatureArticleSnippet(type=standfirst, markup= A recent study has shown that evolocumab, an injectable monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), robustly reduces levels of LDL cholesterol and decreases the risk of cardiovascular disease in patients with and without diabetes mellitus. When given on top of statins, evolocumab does not induce diabetes mellitus. , isJats=true)

    更新日期:2017-11-10
  • Thyroid cancer: Lenvatinib — beyond trials
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Claire Greenhill

    Thyroid cancer: Lenvatinib — beyond trials Thyroid cancer: Lenvatinib — beyond trials, Published online: 09 November 2017; doi:10.1038/nrendo.2017.149

    更新日期:2017-11-10
  • Ageing: Improvement in age-related cognitive functions and life expectancy by ketogenic diets
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Arne Astrup, Mads Fiil Hjorth

    Ageing: Improvement in age-related cognitive functions and life expectancy by ketogenic diets Ageing: Improvement in age-related cognitive functions and life expectancy by ketogenic diets, Published online: 09 November 2017; doi:10.1038/nrendo.2017.142 NatureArticleSnippet(type=standfirst, markup= Rodent studies have indicated that low-carbohydrate diets prevent age-related cognitive decline and extend lifespan due to increased circulating levels of ketone bodies. A possible physiological mechanism for how ketone bodies exert this effect might be by improving central nervous system insulin resistance, which makes this finding interesting with regards to the prevention of cognitive decline and dementia in patients with type 2 diabetes mellitus. , isJats=true)

    更新日期:2017-11-10
  • Obesity: The myth of innocent obesity
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Matthias Blüher

    Obesity: The myth of innocent obesity Obesity: The myth of innocent obesity, Published online: 09 November 2017; doi:10.1038/nrendo.2017.146 NatureArticleSnippet(type=standfirst, markup= The concept of metabolically healthy obesity (MHO) suggests that obesity might be a benign condition. This view has been challenged by a recent study demonstrating that, among 3.5 million individuals, those with MHO still have a higher risk of cardiovascular diseases than individuals who are metabolically healthy and normal weight. , isJats=true)

    更新日期:2017-11-10
  • Diabetes: A new hope for insulin-sensitizing drugs
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Alan Morris

    Diabetes: A new hope for insulin-sensitizing drugs Diabetes: A new hope for insulin-sensitizing drugs, Published online: 09 November 2017; doi:10.1038/nrendo.2017.150

    更新日期:2017-11-10
  • Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes?
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Rutger Verbeek, G. Kees Hovingh

    Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes? Diabetes: Anti-PCSK9 antibodies — beneficial or inducers of diabetes?, Published online: 09 November 2017; doi:10.1038/nrendo.2017.145 NatureArticleSnippet(type=standfirst, markup= A recent study has shown that evolocumab, an injectable monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), robustly reduces levels of LDL cholesterol and decreases the risk of cardiovascular disease in patients with and without diabetes mellitus. When given on top of statins, evolocumab does not induce diabetes mellitus. , isJats=true)

    更新日期:2017-11-10
  • Thyroid cancer: Lenvatinib — beyond trials
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Claire Greenhill

    Thyroid cancer: Lenvatinib — beyond trials Thyroid cancer: Lenvatinib — beyond trials, Published online: 09 November 2017; doi:10.1038/nrendo.2017.149

    更新日期:2017-11-10
  • Ageing: Improvement in age-related cognitive functions and life expectancy by ketogenic diets
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Arne Astrup, Mads Fiil Hjorth

    Ageing: Improvement in age-related cognitive functions and life expectancy by ketogenic diets Ageing: Improvement in age-related cognitive functions and life expectancy by ketogenic diets, Published online: 09 November 2017; doi:10.1038/nrendo.2017.142 NatureArticleSnippet(type=standfirst, markup= Rodent studies have indicated that low-carbohydrate diets prevent age-related cognitive decline and extend lifespan due to increased circulating levels of ketone bodies. A possible physiological mechanism for how ketone bodies exert this effect might be by improving central nervous system insulin resistance, which makes this finding interesting with regards to the prevention of cognitive decline and dementia in patients with type 2 diabetes mellitus. , isJats=true)

    更新日期:2017-11-10
  • Obesity: The myth of innocent obesity
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Matthias Blüher

    Obesity: The myth of innocent obesity Obesity: The myth of innocent obesity, Published online: 09 November 2017; doi:10.1038/nrendo.2017.146 NatureArticleSnippet(type=standfirst, markup= The concept of metabolically healthy obesity (MHO) suggests that obesity might be a benign condition. This view has been challenged by a recent study demonstrating that, among 3.5 million individuals, those with MHO still have a higher risk of cardiovascular diseases than individuals who are metabolically healthy and normal weight. , isJats=true)

    更新日期:2017-11-10
  • Diabetes: A new hope for insulin-sensitizing drugs
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-11-09
    Alan Morris

    Diabetes: A new hope for insulin-sensitizing drugs Diabetes: A new hope for insulin-sensitizing drugs, Published online: 09 November 2017; doi:10.1038/nrendo.2017.150

    更新日期:2017-11-10
  • Obesity: Pharmacological actions of FGF19 and FGF21 revealed
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-10-27
    Alan Morris

    Obesity: Pharmacological actions of FGF19 and FGF21 revealed Nature Reviews Endocrinology, Published online: 27 October 2017; doi:10.1038/nrendo.2017.144

    更新日期:2017-10-30
  • Therapy: SGLT inhibition in T1DM — definite benefit with manageable risk
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-10-27
    Ele Ferrannini, Anna Solini

    Therapy: SGLT inhibition in T1DM — definite benefit with manageable risk Nature Reviews Endocrinology, Published online: 27 October 2017; doi:10.1038/nrendo.2017.139 Two phase III trials using the selective SGLT2 inhibitor dapagliflozin or the dual SGLT2/SGLT1 inhibitor sotagliflozin in patients with type 1 diabetes mellitus show similar clinical benefit (reduction of HbA1c, body weight, blood pressure and insulin dose). The risk of hypoglycaemia and diabetic ketoacidosis with these inhibitors can be managed by careful adjustment of insulin therapy.

    更新日期:2017-10-30
  • Diabetes: Omega-6 PUFAs and T2DM
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-10-27
    Conor A. Bradley

    Diabetes: Omega-6 PUFAs and T2DM Nature Reviews Endocrinology, Published online: 27 October 2017; doi:10.1038/nrendo.2017.143

    更新日期:2017-10-30
  • The special relationship: glia–neuron interactions in the neuroendocrine hypothalamus
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-10-27
    Jerome Clasadonte, Vincent Prevot

    The special relationship: glia–neuron interactions in the neuroendocrine hypothalamus Nature Reviews Endocrinology, Published online: 27 October 2017; doi:10.1038/nrendo.2017.124 The hypothalamus is the main integrator of endocrine regulation. Glia–neuron interactions contribute to physiological processes such as puberty, the maintenance of bodily homeostasis and ageing. Here, Vincent Prevot and Jerome Clasadonte discuss glia–neuron interactions in the control of hypothalamic neuroendocrine function.

    更新日期:2017-10-30
  • Targeting thermogenesis in brown fat and muscle to treat obesity and metabolic disease
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-10-23
    Matthias J. Betz, Sven Enerbäck

    Targeting thermogenesis in brown fat and muscle to treat obesity and metabolic disease Nature Reviews Endocrinology, Published online: 23 October 2017; doi:10.1038/nrendo.2017.132 Targeting thermogenesis in brown fat and skeletal muscle to expend energy and reduce fat mass is a promising therapeutic strategy for treating obesity and related metabolic diseases. Here, Betz and Enerbäck discuss the different molecular pathways regulating thermogenesis in these organs and discuss how they can be therapeutically exploited.

    更新日期:2017-10-30
  • Genetics: Towards β-cell regeneration
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-10-23
    Claire Greenhill

    Genetics: Towards β-cell regeneration Nature Reviews Endocrinology, Published online: 23 October 2017; doi:10.1038/nrendo.2017.140

    更新日期:2017-10-30
  • Diabetes: Predicting severe hypoglycaemia — a step forward
    Nat. Rev. Endocrinol. (IF 18.318) Pub Date : 2017-10-23
    Francesco Zaccardi, Kamlesh Khunti

    Diabetes: Predicting severe hypoglycaemia — a step forward Nature Reviews Endocrinology, Published online: 23 October 2017; doi:10.1038/nrendo.2017.138 The patient-centred approach to the management of hyperglycaemia, encouraged by current guidelines, requires the availability of tools to quantify the benefits and harms of intensive glucose control. Although several scores enable estimation of the long-term risk of developing diabetes-related complications, there are very few validated models to predict the risk of severe hypoglycaemia.

    更新日期:2017-10-30
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
化学 • 材料 期刊列表
Wiley论文编辑服务,每月大奖送不停!
深圳大学-同济大学联合招聘博士后(税后年薪30万)
华中师范大学第一届国际青年学者化学科学论坛
【问答】苯发生亲核取代反应可能的机理是什么?
X-MOL近期新增451种期刊(20171216)
2017年中科院JCR分区化学大类列表
试剂库存管理
化合物查询
down
wechat
bug